Sandoz, a Novartis division, announced an investment of approximately $90M at its site in Ljubljana, Slovenia to establish a dedicated Sandoz Biopharma Development Center by 2026. “With this investment, the Ljubljana site will become one of the key locations for biosimilar product development at Sandoz. The new site will lead to the creation of approximately 200 new full-time jobs and further strengthen the company’s capabilities in end-to-end drug substance and drug product development of biosimilars. The planned investment complements recently announced Sandoz plans to invest at least USD 400 million in a new biologics manufacturing plant in Lendava, Slovenia, as well as expanding its biosimilar development capabilities at its facility in Holzkirchen, Germany. It also builds on existing small molecule product development capabilities in Ljubljana, where Sandoz has successfully established comprehensive capabilities to develop technologically complex generic pharmaceuticals,” the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVS:
- Novartis price target raised to CHF 95 from CHF 92 at JPMorgan
- IO Biotech appoints Qasim Ahmad MD, CMO, Faulkner CTO
- Novartis (NYSE:NVS) Gains on Q2 Beat; Boosts Outlook
- Novartis raises FY23 group sales ex-Sandoz view to high single digits
- Novartis board endorses separation of Sandoz by way of 100% spinoff